381219-90-5

Basic information

• Product Name: 1-trityl-1H-1,2,4-triazole-3-carboxylic acid
• Synonyms: 1-trityl-1H-1,2,4-triazole-3-carboxylic acid
• CAS NO: 381219-90-5
• Molecular Weight: 355.396
• Mol File: 381219-90-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-trityl-1H-1,2,4-triazole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-trityl-1H-1,2,4-triazole-3-carboxylic acid(381219-90-5)
• EPA Substance Registry System: 1-trityl-1H-1,2,4-triazole-3-carboxylic acid(381219-90-5)

Safety Data

• Hazardous Substances Data: 381219-90-5(Hazardous Substances Data)

Usage

Derivative of 1,2,4-triazole-3-carboxylic acid

The compound is derived from 1,2,4-triazole-3-carboxylic acid, which means it is a modified version of the parent compound with additional functional groups or structural changes.

Trityl group

The presence of a trityl group (a phenyl ring with two methyl groups) attached to the triazole ring contributes to the stability and protection of the compound during chemical reactions.

Organic synthesis and pharmaceutical research

1-trityl-1H-1,2,4-triazole-3-carboxylic acid is commonly used as a building block in the synthesis of various organic compounds and is valuable in the field of pharmaceutical research.

Drug candidate potential

The compound has shown potential as a drug candidate for the treatment of various diseases, making it an important subject of study in medicinal chemistry.

Versatile chemical structure

The compound's chemical structure allows for various modifications and adaptations, making it a valuable tool for creating new compounds and exploring their potential applications.

Upstream product

• 76-83-5 trityl chloride 

Downstream Products

• 637335-74-1 1-trityl-1H-[1,2,4]triazole-3-carboxylic acid (4-{[6-amino-1-butyl-3-(2-fluoro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-ylcarbamoyl]-methyl}-phenyl)-amide 

Relevant articles and documents

Discovery of novel, highly potent, and selective matrix metalloproteinase (MMP)-13 inhibitors with a 1,2,4-triazol-3-yl moiety as a zinc binding group using a structure-based design approach

On the basis of a superposition study of X-ray crystal structures of complexes of quinazoline derivative 1 and triazole derivative 2 with matrix metalloproteinase (MMP)-13 catalytic domain, a novel series of fused pyrimidine compounds which possess a 1,2,4-triazol-3-yl group as a zinc binding group (ZBG) was designed. Among the herein described and evaluated compounds, 31f exhibited excellent potency for MMP-13 (IC50 = 0.036 nM) and selectivities (greater than 1,500-fold) over other MMPs (MMP-1, -2, -3, -7, -8, -9, -10, and -14) and tumor necrosis factor-α converting enzyme (TACE). Furthermore, the inhibitor was shown to protect bovine nasal cartilage explants against degradation induced by interleukin-1 and oncostatin M. In this article, we report the discovery of extremely potent, highly selective, and orally bioavailable fused pyrimidine derivatives that possess a 1,2,4-triazol-3-yl group as a novel ZBG for selective MMP-13 inhibition.

AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY

The present invention is a 1,3,8 substituted xanthine derivative of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.